CN111548970B - 一株能够预防和/或治疗幽门螺杆菌感染的卷曲乳杆菌 - Google Patents
一株能够预防和/或治疗幽门螺杆菌感染的卷曲乳杆菌 Download PDFInfo
- Publication number
- CN111548970B CN111548970B CN202010479611.4A CN202010479611A CN111548970B CN 111548970 B CN111548970 B CN 111548970B CN 202010479611 A CN202010479611 A CN 202010479611A CN 111548970 B CN111548970 B CN 111548970B
- Authority
- CN
- China
- Prior art keywords
- lactobacillus crispatus
- helicobacter pylori
- ccfm1118
- product
- bacterial
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 241000218492 Lactobacillus crispatus Species 0.000 title claims abstract description 132
- 206010019375 Helicobacter infections Diseases 0.000 title abstract description 12
- 241000590002 Helicobacter pylori Species 0.000 claims abstract description 61
- 229940037467 helicobacter pylori Drugs 0.000 claims abstract description 61
- 239000003112 inhibitor Substances 0.000 claims abstract description 4
- 244000005700 microbiome Species 0.000 claims abstract description 4
- 239000000843 powder Substances 0.000 claims description 42
- 239000007788 liquid Substances 0.000 claims description 28
- 238000002360 preparation method Methods 0.000 claims description 18
- 235000013305 food Nutrition 0.000 claims description 16
- 235000012055 fruits and vegetables Nutrition 0.000 claims description 12
- 208000015181 infectious disease Diseases 0.000 claims description 12
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 9
- 235000013361 beverage Nutrition 0.000 claims description 7
- 239000002775 capsule Substances 0.000 claims description 7
- 238000004321 preservation Methods 0.000 claims description 7
- 239000003937 drug carrier Substances 0.000 claims description 5
- 235000010855 food raising agent Nutrition 0.000 claims description 5
- 239000008187 granular material Substances 0.000 claims description 5
- 229940124531 pharmaceutical excipient Drugs 0.000 claims description 5
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 4
- 229940127557 pharmaceutical product Drugs 0.000 claims description 4
- 244000046052 Phaseolus vulgaris Species 0.000 claims description 3
- 235000010627 Phaseolus vulgaris Nutrition 0.000 claims description 3
- 235000013365 dairy product Nutrition 0.000 claims description 3
- 235000013402 health food Nutrition 0.000 claims description 3
- 239000006187 pill Substances 0.000 claims description 3
- 235000011888 snacks Nutrition 0.000 claims description 3
- 239000003826 tablet Substances 0.000 claims description 3
- 241001473947 Helicobacter pylori SS1 Species 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims description 2
- 239000003814 drug Substances 0.000 abstract description 8
- 230000002401 inhibitory effect Effects 0.000 abstract description 6
- 230000005764 inhibitory process Effects 0.000 abstract description 6
- 239000006228 supernatant Substances 0.000 abstract description 5
- 201000010099 disease Diseases 0.000 abstract description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 4
- 229940079593 drug Drugs 0.000 abstract description 4
- 238000003745 diagnosis Methods 0.000 abstract description 2
- 230000001580 bacterial effect Effects 0.000 description 95
- 239000001963 growth medium Substances 0.000 description 73
- 239000000243 solution Substances 0.000 description 51
- 238000012258 culturing Methods 0.000 description 47
- 239000002994 raw material Substances 0.000 description 25
- 239000000725 suspension Substances 0.000 description 25
- 230000004913 activation Effects 0.000 description 22
- 235000020183 skimmed milk Nutrition 0.000 description 20
- 238000009630 liquid culture Methods 0.000 description 19
- 244000068988 Glycine max Species 0.000 description 18
- 235000010469 Glycine max Nutrition 0.000 description 18
- 239000003223 protective agent Substances 0.000 description 17
- 239000007787 solid Substances 0.000 description 17
- 235000013336 milk Nutrition 0.000 description 16
- 239000008267 milk Substances 0.000 description 16
- 210000004080 milk Anatomy 0.000 description 16
- 239000000902 placebo Substances 0.000 description 15
- 229940068196 placebo Drugs 0.000 description 15
- 239000000047 product Substances 0.000 description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 15
- 238000011081 inoculation Methods 0.000 description 14
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 12
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 12
- 239000008103 glucose Substances 0.000 description 12
- 241000218588 Lactobacillus rhamnosus Species 0.000 description 11
- 230000003213 activating effect Effects 0.000 description 11
- 238000004108 freeze drying Methods 0.000 description 11
- 238000000034 method Methods 0.000 description 11
- 238000005406 washing Methods 0.000 description 11
- 229940041514 candida albicans extract Drugs 0.000 description 10
- 239000012137 tryptone Substances 0.000 description 10
- 239000012138 yeast extract Substances 0.000 description 10
- 108090000790 Enzymes Proteins 0.000 description 8
- 102000004190 Enzymes Human genes 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 239000002609 medium Substances 0.000 description 8
- 238000002835 absorbance Methods 0.000 description 7
- 230000007062 hydrolysis Effects 0.000 description 7
- 238000006460 hydrolysis reaction Methods 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 241001052560 Thallis Species 0.000 description 6
- 238000001816 cooling Methods 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 239000007858 starting material Substances 0.000 description 6
- 235000015140 cultured milk Nutrition 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 239000000654 additive Substances 0.000 description 4
- 230000000996 additive effect Effects 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 235000020124 milk-based beverage Nutrition 0.000 description 4
- 239000011259 mixed solution Substances 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 239000002504 physiological saline solution Substances 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 230000001954 sterilising effect Effects 0.000 description 4
- 108020004465 16S ribosomal RNA Proteins 0.000 description 3
- 206010067484 Adverse reaction Diseases 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 230000006838 adverse reaction Effects 0.000 description 3
- 239000012298 atmosphere Substances 0.000 description 3
- 238000004140 cleaning Methods 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 238000000855 fermentation Methods 0.000 description 3
- 230000004151 fermentation Effects 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 238000012163 sequencing technique Methods 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- QIJRTFXNRTXDIP-UHFFFAOYSA-N (1-carboxy-2-sulfanylethyl)azanium;chloride;hydrate Chemical compound O.Cl.SCC(N)C(O)=O QIJRTFXNRTXDIP-UHFFFAOYSA-N 0.000 description 2
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 2
- 206010059866 Drug resistance Diseases 0.000 description 2
- 241000589989 Helicobacter Species 0.000 description 2
- 241000186660 Lactobacillus Species 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- 239000001888 Peptone Substances 0.000 description 2
- 108010080698 Peptones Proteins 0.000 description 2
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 235000015278 beef Nutrition 0.000 description 2
- 239000007621 bhi medium Substances 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000006184 cosolvent Substances 0.000 description 2
- 238000010227 cup method (microbiological evaluation) Methods 0.000 description 2
- 229960001305 cysteine hydrochloride Drugs 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- YXVFQADLFFNVDS-UHFFFAOYSA-N diammonium citrate Chemical compound [NH4+].[NH4+].[O-]C(=O)CC(O)(C(=O)O)CC([O-])=O YXVFQADLFFNVDS-UHFFFAOYSA-N 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 230000035622 drinking Effects 0.000 description 2
- 229910052564 epsomite Inorganic materials 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 210000001156 gastric mucosa Anatomy 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 229940039696 lactobacillus Drugs 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 229910000357 manganese(II) sulfate Inorganic materials 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 239000003094 microcapsule Substances 0.000 description 2
- 239000004005 microsphere Substances 0.000 description 2
- 239000002105 nanoparticle Substances 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 235000019319 peptone Nutrition 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 238000005057 refrigeration Methods 0.000 description 2
- 230000000391 smoking effect Effects 0.000 description 2
- 238000002791 soaking Methods 0.000 description 2
- 239000001632 sodium acetate Substances 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- 239000000661 sodium alginate Substances 0.000 description 2
- 235000010413 sodium alginate Nutrition 0.000 description 2
- 229940005550 sodium alginate Drugs 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 235000013322 soy milk Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 208000018556 stomach disease Diseases 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 241000589875 Campylobacter jejuni Species 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 241000750379 Erithacus akahige Species 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 244000199885 Lactobacillus bulgaricus Species 0.000 description 1
- 235000013960 Lactobacillus bulgaricus Nutrition 0.000 description 1
- 206010054949 Metaplasia Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 208000037581 Persistent Infection Diseases 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 241000194020 Streptococcus thermophilus Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 108010046334 Urease Proteins 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 231100000357 carcinogen Toxicity 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 208000023652 chronic gastritis Diseases 0.000 description 1
- 230000008576 chronic process Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 208000000718 duodenal ulcer Diseases 0.000 description 1
- 230000008029 eradication Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 235000021022 fresh fruits Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 229940004208 lactobacillus bulgaricus Drugs 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 238000009629 microbiological culture Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 150000007523 nucleic acids Chemical group 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000003950 pathogenic mechanism Effects 0.000 description 1
- 239000006041 probiotic Substances 0.000 description 1
- 235000018291 probiotics Nutrition 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C11/00—Milk substitutes, e.g. coffee whitener compositions
- A23C11/02—Milk substitutes, e.g. coffee whitener compositions containing at least one non-milk component as source of fats or proteins
- A23C11/10—Milk substitutes, e.g. coffee whitener compositions containing at least one non-milk component as source of fats or proteins containing or not lactose but no other milk components as source of fats, carbohydrates or proteins
- A23C11/103—Milk substitutes, e.g. coffee whitener compositions containing at least one non-milk component as source of fats or proteins containing or not lactose but no other milk components as source of fats, carbohydrates or proteins containing only proteins from pulses, oilseeds or nuts, e.g. nut milk
- A23C11/106—Addition of, or treatment with, microorganisms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
- A23C9/123—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt
- A23C9/1234—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt characterised by using a Lactobacillus sp. other than Lactobacillus Bulgaricus, including Bificlobacterium sp.
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/38—Other non-alcoholic beverages
- A23L2/382—Other non-alcoholic beverages fermented
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
- A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6925—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a microcapsule, nanocapsule, microbubble or nanobubble
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
- A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/133—Curvatus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/225—Lactobacillus
Abstract
本发明公开了一株能够预防和/或治疗幽门螺杆菌感染的卷曲乳杆菌,属于微生物技术领域以及医药技术领域。本发明提供了一株卷曲乳杆菌(Lactobacillus crispatus)CCFM1118,此卷曲乳杆菌CCFM1118能够抑制幽门螺杆菌,具体体现在:(1)卷曲乳杆菌CCFM1118上清液对幽门螺杆菌的抑菌圈大小可达13.14mm;(2)卷曲乳杆菌CCFM1118可显著降低幽门螺杆菌对AGS细胞的粘附力,可见,卷曲乳杆菌(Lactobacillus crispatus)CCFM1118在抑制幽门螺杆菌(不以疾病的诊断和治疗为目的)以及制备幽门螺杆菌抑制剂方面具有巨大的应用前景。
Description
技术领域
本发明涉及一株能够预防和/或治疗幽门螺杆菌感染的卷曲乳杆菌,属于微生物技术领域以及医药技术领域。
背景技术
幽门螺杆菌(Helicobacterpylori,Hp)是一种呈S型或者弧形弯曲的革兰氏阴性细菌。1982年,Barry J.Marshall和J.Robin Warren从人的胃粘膜标本中分离并培养出幽门螺杆菌,从而成功并揭示了其潜在致病机制,二者由此获得了2005年的生理医学奖。1994年,幽门螺杆菌被世界卫生组织定为I类致癌原。现阶段,幽门螺杆菌在全球的感染率已高达50%左右,发展中国家的幽门螺杆菌感染率高于发达国家。
幽门螺杆菌感染是一个长期且慢性的过程,感染后人体一般难以自发清除而导致终身感染,除非进行根除治疗,或人体胃黏膜发生严重肠化生使得细菌难以定植,幽门螺杆菌才会在人体自动消失。研究表明,幽门螺杆菌长期感染会引起慢性胃炎的发生,并且,随着感染程度的加深和病情的恶化,部分患者会发展成十二指肠溃疡,甚至胃癌。而幽门螺杆菌在胃部的定殖量直接影响胃病的发展进程,一般情况下,患者体内幽门螺杆菌密度越高,其导致胃病的可能性及程度越高。因此,抑制幽门螺杆菌生长及降低其在患者体内定殖密度对预防和/或治疗幽门螺杆菌感染引起的胃部病变具有重要意义。
目前,主要是通过抗生素结合的三联或者四联疗法抑制幽门螺杆菌生长及降低其在患者体内定殖密度。但是,上述治疗方法由于频繁使用抗生素,易导致幽门螺杆菌耐药性增加,并且,使用上述治疗方法治疗患者的过程中,患者常常会出现严重的不良反应(如腹痛、恶心、腹泻等),导致治疗有效率降低,治疗效果往往达不到预期。
因此,仍然需要一种药物或治疗方式,既不会增加幽门螺杆菌耐药性,同时,在治疗过程中不会导致患者产生不良反应,以提高幽门螺杆菌临床治疗的效果。
发明内容
[技术问题]
本发明要解决的技术问题是提供一株能够预防和/或治疗幽门螺杆菌感染的卷曲乳杆菌(Lactobacillus crispatus)。
[技术方案]
为解决上述问题,本发明提供了一株卷曲乳杆菌(Lactobacillus crispatus)CCFM1118,所述卷曲乳杆菌CCFM1118保藏于广东省微生物菌种保藏中心,保藏编号为GDMCCNo.61012,保藏日期为2020年05月06日。
所述卷曲乳杆菌CCFM1118来源于广西省巴马县甲篆乡长寿村的8岁儿童新鲜粪便样本,该菌株经测序分析,其16S rDNA序列如SEQ ID NO.1所示,将测序得到的序列在GeneBank中进行核酸序列比对,结果显示菌株为卷曲乳杆菌,命名为卷曲乳杆菌CCFM1118。
所述卷曲乳杆菌CCFM1118在MRS固体培养基上的菌落呈乳白色半圆形凸起,表面光滑、湿润,边缘整齐。
本发明还提供了上述卷曲乳杆菌CCFM1118在抑制幽门螺杆菌方面不以疾病的诊断和治疗为目的的应用。
本发明还提供了一种幽门螺杆菌抑制剂,所述幽门螺杆菌抑制剂含有上述卷曲乳杆菌CCFM1118。
本发明还提供了上述卷曲乳杆菌CCFM1118在制备预防和/或治疗幽门螺杆菌感染的产品中的应用。
本发明的一种实施方式中,所述产品中,上述卷曲乳杆菌CCFM1118的活菌数为不低于5×109CFU/mL或5×109CFU/g。
本发明的一种实施方式中,所述产品包含食品或药品。
本发明的一种实施方式中,所述药品含有上述卷曲乳杆菌CCFM1118、药物载体和/或药用辅料。
本发明的一种实施方式中,所述药物载体包含微囊、微球、纳米粒和/或脂质体。
本发明的一种实施方式中,所述药用辅料包含赋形剂和/或附加剂。
本发明的一种实施方式中,所述赋形剂包含黏合剂、填充剂、崩解剂和/或润滑剂。
本发明的一种实施方式中,所述附加剂包含增溶剂、助溶剂、潜溶剂和/或防腐剂。
本发明的一种实施方式中,所述药品的剂型为粉剂、颗粒剂、胶囊剂、片剂、丸剂或口服液。
本发明的一种实施方式中,所述食品为保健食品;或所述食品为使用含有上述卷曲乳杆菌CCFM1118的发酵剂生产得到的乳制品、豆制品或果蔬制品;或所述食品为含有上述卷曲乳杆菌CCFM1118的饮料或零食。
本发明的一种实施方式中,所述发酵剂的制备方法为将上述卷曲乳杆菌CCFM1118按照占培养基总质量2~4%的接种量接种到培养基中,于37℃下培养18h,得到培养液;将培养液离心,得到菌体;将菌体用生理盐水清洗3次后用冻干保护剂重悬,得到重悬液;将重悬液采用真空冷冻法进行冻干,得到发酵剂。
本发明的一种实施方式中,所述冻干保护剂和菌体的质量比为2:1。
在本发明的一种实施方式中,所述冻干保护剂包含130g/L的脱脂奶粉。
本发明的一种实施方式中,所述培养基包含占培养基总质量87.7%的水、占培养基总质量10%的脱脂乳、占培养基总质量0.5%的葡萄糖、占培养基总质量1.5%的胰蛋白胨以及占培养基总质量0.3%的酵母浸膏。
本发明的一种实施方式中,所述培养基的pH为6.8。
本发明还提供了一种用于预防和/或治疗幽门螺杆菌感染的产品,所述产品含有权利要求1所述卷曲乳杆菌CCFM1118。
本发明的一种实施方式中,所述产品中,上述卷曲乳杆菌CCFM1118的活菌数为不低于5×109CFU/mL或5×109CFU/g。
本发明的一种实施方式中,所述产品包含食品或药品。
本发明的一种实施方式中,所述药品含有上述卷曲乳杆菌CCFM1118、药物载体和/或药用辅料。
本发明的一种实施方式中,所述药物载体包含微囊、微球、纳米粒和/或脂质体。
本发明的一种实施方式中,所述药用辅料包含赋形剂和/或附加剂。
本发明的一种实施方式中,所述赋形剂包含黏合剂、填充剂、崩解剂和/或润滑剂。
本发明的一种实施方式中,所述附加剂包含增溶剂、助溶剂、潜溶剂和/或防腐剂。
本发明的一种实施方式中,所述药品的剂型为粉剂、颗粒剂、胶囊剂、片剂、丸剂或口服液。
本发明的一种实施方式中,所述食品为保健食品;或所述食品为使用含有上述卷曲乳杆菌CCFM1118的发酵剂生产得到的乳制品、豆制品或果蔬制品;或所述食品为含有上述卷曲乳杆菌CCFM1118的饮料或零食。
本发明的一种实施方式中,所述发酵剂的制备方法为将上述卷曲乳杆菌CCFM1118按照占培养基总质量2~4%的接种量接种到培养基中,于37℃下培养18h,得到培养液;将培养液离心,得到菌体;将菌体用生理盐水清洗3次后用冻干保护剂重悬,得到重悬液;将重悬液采用真空冷冻法进行冻干,得到发酵剂。
本发明的一种实施方式中,所述冻干保护剂和菌体的质量比为2:1。
在本发明的一种实施方式中,所述冻干保护剂包含130g/L的脱脂奶粉。
本发明的一种实施方式中,所述培养基包含占培养基总质量87.7%的水、占培养基总质量10%的脱脂乳、占培养基总质量0.5%的葡萄糖、占培养基总质量1.5%的胰蛋白胨以及占培养基总质量0.3%的酵母浸膏。
本发明的一种实施方式中,所述培养基的pH为6.8。
有益效果:
1、本发明提供了一株卷曲乳杆菌(Lactobacillus crispatus)CCFM1118,此卷曲乳杆菌CCFM1118能够抑制幽门螺杆菌,具体体现在:
(1)卷曲乳杆菌CCFM1118上清液对幽门螺杆菌的抑菌圈大小可达13.14mm;
(2)卷曲乳杆菌CCFM1118可显著降低幽门螺杆菌对AGS细胞的粘附力,
可见,卷曲乳杆菌(Lactobacillus crispatus)CCFM1118在抑制幽门螺杆菌(不以疾病的诊断和治疗为目的)以及制备幽门螺杆菌抑制剂方面具有巨大的应用前景。
2、本发明提供了一株卷曲乳杆菌(Lactobacillus crispatus)CCFM1118,此卷曲乳杆菌CCFM1118具有预防和/或治疗幽门螺杆菌感染的作用,具体体现在:
(1)卷曲乳杆菌CCFM1118可显著降低幽门螺杆菌感染患者体内幽门螺杆菌定殖量;
(2)卷曲乳杆菌CCFM1118可显著降低幽门螺杆菌感染患者幽门螺杆菌感染程度,
可见,卷曲乳杆菌(Lactobacillus crispatus)CCFM1118在制备预防和/或治疗幽门螺杆菌感染的产品(如食品或药品等)中具有巨大的应用前景。
3、卷曲乳杆菌(Lactobacillus crispatus)是益生菌的一种,目前已被纳入卫生部下发的《可用于食品的菌种名单》,可见,本发明的有效成分为卷曲乳杆菌CCFM1118的产品不会使得幽门螺杆菌产生耐药性,同时,在治疗过程中不会导致患者产生不良反应。
生物材料保藏
一株卷曲乳杆菌(Lactobacillus crispatus)CCFM1118,分类学命名为Lactobacilluscrispatus,已于2020年05月06日保藏于广东省微生物菌种保藏中心,保藏编号为GDMCCNo.61012,保藏地址为广州市先烈中路100号大院59号楼5楼。
附图说明
图1:不同组别幽门螺杆菌黏附AGS细胞的黏附率。
图2:不同组别幽门螺杆菌阳性患者的14C呼气值变化情况。
图3:时间对卷曲乳杆菌CCFM1118菌粉活菌数的影响。
具体实施方式
下述实施例中涉及的幽门螺杆菌为来源于NTCC国家典型培养物保藏中心的幽门螺杆菌SS1;下述实施例中涉及的鼠李糖乳杆菌L.GG来源于美国模式培养物集存库(ATCC),保藏编号为ATCC 53103;下述实施例中涉及的F12液体培养基和胎牛血清购自美国Gibco公司;下述实施例中涉及的NaCl购自国药集团;下述实施例中涉及的苯酚红与尿素购自麦克林公司;下述实施例中涉及的哥伦比亚培养基购自英国OXOID公司;下述实施例中涉及的无菌脱纤维绵羊血购自杭州新锐公司;下述实施例中涉及的BHI液体培养基购自青岛海博公司。
下述实施例中涉及的培养基如下:
MRS固体培养基(g/L):蛋白胨10g/L、牛肉膏10g/L、葡萄糖20g/L、乙酸钠2g/L、酵母粉5g/L、柠檬酸氢二铵2g/L、K2PO4·3H2O 2.6g/L、MgSO4·7H2O 0.1g/L、MnSO40.05g/L、吐温801mL/L、琼脂20g/L、半胱氨酸氨酸盐0.5g/L。
MRS液体培养基(g/L):蛋白胨10g/L、牛肉膏10g/L、葡萄糖20g/L、乙酸钠2g/L、酵母粉5g/L、柠檬酸氢二铵2g/L、K2PO4·3H2O 2.6g/L、MgSO4·7H2O 0.1g/L、MnSO40.05g/L、吐温801mL/L、半胱氨酸氨酸盐0.5g/L。
下述实施例中涉及的检测方法如下:
活菌数的检测方法:采用国标《GB 4789.35-2016食品安全国家标准食品微生物学检测乳酸菌检测》。
下述实施例中涉及的幽门螺杆菌菌体的制备方法如下:
将幽门螺杆菌在哥伦比亚血平板上划线后,于37℃三气培养箱中(85%N2、10%CO2、5%O2)培养3天,得到单菌落;挑取单菌落接种于含5%(v/v)胎牛血清的BHI培养基中,于37℃三气培养箱中(85%N2、10%CO2、5%O2)培养4天得到种子液;将种子液以2%(v/v)的接种量接种于BHI培养基中,于37℃三气培养箱中(85%N2、10%CO2、5%O2)培养4天,得到幽门螺杆菌菌液;将幽门螺杆菌菌液8000g离心10min,得到幽门螺杆菌菌体;
其中,哥伦比亚血平板:39g哥伦比亚培养基固体粉末溶于1L水中,121℃灭菌15min,待冷却到55℃~60℃后加入7.5%(v/v)的无菌脱纤维绵羊血,混匀后倒板。
下述实施例中涉及的鼠李糖乳杆菌菌体的制备方法如下:
将鼠李糖乳杆菌划线于MRS固体培养基上,37℃条件下培养48h,得到单菌落;挑取单菌落接种于MRS液体培养基中,37℃条件下培养18h进行活化,连续活化两代,得到活化液;将活化液按2%(v/v)的接种量接种于MRS液体培养基中,37℃条件下培养18h,得到菌液;将菌液经8000g离心10min,得到鼠李糖乳杆菌菌体。
下述实施例中涉及的卷曲乳杆菌菌体的制备方法如下:
将卷曲乳杆菌划线于MRS固体培养基上,37℃条件下培养48h,得到单菌落;挑取单菌落接种于MRS液体培养基中,37℃条件下培养18h进行活化,连续活化两代,得到活化液;将活化液按2%(v/v)的接种量接种于MRS液体培养基中,37℃条件下培养18h,得到菌液;将菌液经8000g离心10min,得到卷曲乳杆菌菌体。
实施例1:卷曲乳杆菌的筛选及鉴定
1、筛选
以来源于江苏省昆山市的健康人群新鲜粪便为样本,将样本经预处理后,在30%左右甘油中保存于-80℃冰箱,取出解冻后,混匀样本吸取0.5mL样本加到4.5mL 0.9%生理盐水进行梯度稀释,选择合适的梯度稀释液涂布在MRS固体培养基上,于37℃培养48h,挑取典型菌落至MRS平板上划线纯化,挑取单菌落转接至液体MRS液体培养基增菌,30%甘油保藏,得到菌株CCFM1118(菌株原始编号为G14-5M)。
2、鉴定
提取CCFM1118的基因组,将CCFM1118的16S rDNA进行扩增和测序(由上海生工生物工程股份有限公司完成),经测序分析,该菌株的16S rDNA序列如SEQ ID NO.1所示,将该序列在GenBank中进行比对,结果显示菌株为卷曲乳杆菌,命名为卷曲乳杆菌(Lactobacillus crispatus)CCFM1118。
实施例2:卷曲乳杆菌的培养
将卷曲乳杆菌CCFM1118接入MRS固体培养基中于37℃培养48h后,观察其菌落并在显微镜下对其菌体进行观察,发现其菌落乳白色半圆形凸起,表面光滑、湿润,边缘整齐。
将卷曲乳杆菌CCFM1118接入MRS液体培养基中于37℃培养48h,培养过程中,间隔一段时间通过pH计测量培养液的pH,发现卷曲乳杆菌CCFM1118在培养过程中产酸。
将卷曲乳杆菌CCFM1118接入MRS液体培养基中分别于10~50℃下培养48h,培养过程中,间隔一段时间通过酶标仪测量培养液的OD600,发现卷曲乳杆菌CCFM1118在30~37℃生长最佳,培养18~24h达到生长稳定期。
实施例3:卷曲乳杆菌对幽门螺杆菌的抑制作用
以MRS液体培养基为阴性对照,将卷曲乳杆菌CCFM1118划线于MRS固体培养基上,37℃条件下培养48h,得到单菌落;挑取单菌落接种于MRS液体培养基中,37℃条件下培养18h进行活化,连续活化两代,得到活化液;将活化液按2%(v/v)的接种量接种于MRS液体培养基中,37℃条件下培养18h,得到菌液;将菌液经8000g离心10min后过0.22μm无菌滤膜,得到上清液;用牛津杯法测定上清液抑制幽门螺杆菌生长的效果,测定结果见表1(牛津杯法具体可参见文献:张婷婷,翟齐啸,金星等.具有拮抗空肠弯曲杆菌能力鸡源乳酸菌的筛选及特性.微生物学通报,2017,(44):118-125)。
由表1可知,MRS液体培养基对幽门螺杆菌无抑菌圈,而卷曲乳杆菌CCFM1118上清液对幽门螺杆菌的抑菌圈大小可达13.14mm,表明卷曲乳杆菌CCFM1118具有抑制幽门螺杆菌生长的作用。
表1卷曲乳杆菌CCFM1118对幽门螺杆菌的抑菌圈大小
组别 | pH | 抑菌圈大小(mm) |
阴性对照 | 6.2 | 0 |
CCFM1118 | 3.81 | 13.14±1.05 |
实施例4:卷曲乳杆菌对幽门螺杆菌粘附力的影响
将幽门螺杆菌菌体用F12重悬至浓度为1×107CFU/mL,得到幽门螺杆菌重悬液;将鼠李糖乳杆菌L.GG菌体用F12重悬至浓度为1×107CFU/mL,得到鼠李糖乳杆菌L.GG重悬液;将卷曲乳杆菌CCFM1118菌体用F12重悬至浓度为1×107CFU/mL,得到卷曲乳杆菌CCFM1118重悬液。
以不经鼠李糖乳杆菌L.GG和卷曲乳杆菌CCFM1118处理且未感染幽门螺杆菌的AGS细胞为空白组,以不经鼠李糖乳杆菌L.GG和卷曲乳杆菌CCFM1118处理的幽门螺杆菌感染AGS细胞为模型组(Hp组),以经鼠李糖乳杆菌L.GG处理的幽门螺杆菌感染AGS细胞和经卷曲乳杆菌CCFM1118处理的幽门螺杆菌感染AGS细胞为实验组(Hp+LGG组和Hp+CCFM1119组);将AGS细胞用含5%(v/v)胎牛血清的F12培养基重悬后添加至96孔板中(2×104个/孔),于37℃、5%CO2的条件下进行培养12~16h,待AGS细胞处于贴壁状态后,用PBS洗涤AGS细胞3次去除死细胞;将幽门螺杆菌重悬液添加至洗涤后的AGS细胞中,于37℃、5%CO2的培养箱中培养2h后,用PBS液洗涤3次,除去未吸附的幽门螺杆菌,得到幽门螺杆菌感染AGS细胞;在幽门螺杆菌感染AGS细胞中分别加入0.2mL鼠李糖乳杆菌L.GG重悬液或卷曲乳杆菌CCFM1118重悬液,于37℃、5%CO2的培养箱中培养2h,得到经鼠李糖乳杆菌L.GG处理的幽门螺杆菌感染AGS细胞和经卷曲乳杆菌CCFM1118处理的幽门螺杆菌感染AGS细胞;将经鼠李糖乳杆菌L.GG处理的幽门螺杆菌感染AGS细胞和经卷曲乳杆菌CCFM1118处理的幽门螺杆菌感染AGS细胞分别用PBS液洗涤5次后在经鼠李糖乳杆菌L.GG处理的幽门螺杆菌感染AGS细胞和经卷曲乳杆菌CCFM1118处理的幽门螺杆菌感染AGS细胞中分别加入200μL尿素酶试剂(9g/LNaCl、14μg/mL苯酚红、20mM尿素,pH 6.8),于37℃、5%CO2的培养箱中培养2h,得到培养液;通过酶标仪测定不同组的培养液的在波长550nm处的吸光度,以模型组吸光度减去空白组吸光度测得的粘附率为100%,其余组吸光度减去空白组吸光度后所得差值与模型组吸光度减去空白组吸光度后所得差值相比得到相对粘附率,测定结果见图1。
由图1可知,经卷曲乳杆菌CCFM1118处理后,幽门螺杆菌对AGS细胞的粘附率显著下降,从模型组(Hp组)的100%下降到约70%左右,而鼠李糖乳杆菌L.GG并没有明显的降低幽门螺杆菌对AGS细胞粘附率的作用,幽门螺杆菌的粘附率几乎没有变化。此结果表明,卷曲乳杆菌CCFM1118可有效降低幽门螺杆菌对AGS细胞的粘附力。
实施例5:卷曲乳杆菌对幽门螺杆菌阳性患者体内幽门螺杆菌定殖量和清除率的影响
卷曲乳杆菌CCFM1118划线于MRS固体培养基上,37℃条件下培养48h,得到单菌落;挑取单菌落接种于MRS液体培养基中,37℃条件下培养18h进行活化,连续活化两代,得到活化液;将活化液按2%(v/v)的接种量接种于培养基中,37℃条件下培养18h,得到菌液;将菌液经8000g离心10min,得到菌泥;将菌泥用生理盐水清洗3次后用保护剂重悬至浓度为1×1010CFU/mL,得到菌悬液;将菌悬液在温度37℃下预培养60min后冻干,得到卷曲乳杆菌CCFM1118菌粉;
其中,培养基的制备方法为:使用以培养基总重量计87.7%的水将10%酶水解脱脂乳、0.5%葡萄糖、1.5%胰蛋白胨与0.3%酵母浸膏溶解,然后调整其pH为6.8,得到培养基;
保护剂的成分包含:130g/L脱脂奶粉。
招募30名幽门螺杆菌阳性感染者(招募人群分布情况见表2,两组人群基线情况差异无统计学意义),将30名幽门螺杆菌阳性感染者随机分为2组,其中,安慰剂组(Placebo)13人,卷曲乳杆菌CCFM1118组(CCFM1119)17人。安慰剂组(Placebo)每天服用安慰剂两次,卷曲乳杆菌CCFM1118组每天服用两次菌粉,整个实验周期为1个月(安慰剂和卷曲乳杆菌菌粉除成分不同外,产品的外观和包装均相同,无明显差别)。分别于实验开始前和结束后通过14C呼气试剂袋和检测仪测定安慰剂组和卷曲乳杆菌CCFM1118组幽门螺杆菌阳性感染者的14C呼气值,评估患者体内幽门螺杆菌定殖量和清除率,测定结果见图2和表3;
其中,幽门螺杆菌定殖量的评判标准为:实验结束后幽门螺杆菌阳性感染者的14C呼气值较实验开始前幽门螺杆菌阳性感染者的14C呼气值的下降量;
幽门螺杆菌清除率的评判标准为:临床14C呼气值的临界值为100,即14C呼气值大于等于100为幽门螺杆菌阳性,14C呼气值低于100为幽门螺杆菌阴性,以实验结束后幽门螺杆菌阳性感染者是否转变为阴性评判幽门螺杆菌阳性感染者的清除率是否升高。
由图2可知,实验结束后,安慰剂组(Placebo)幽门螺杆菌阳性感染者的14C呼气值与实验开始前相比几乎没有变化,而卷曲乳杆菌CCFM1118组(CCFM1118)幽门螺杆菌阳性感染者的14C呼气值与实验开始前相比降低了100左右,具有显著性差异。此结果表明,卷曲乳杆菌CCFM1118可显著降低幽门螺杆菌感染患者体内幽门螺杆菌定殖量。
由表3可知,实验结束后,安慰剂组(Placebo)13个人中有2个人变为幽门螺杆菌阴性,阴性率为15.38%,卷曲乳杆菌CCFM1118组17个人中有12个人变为幽门螺杆菌阴性,阴性率高达70.59%,显著高于安慰剂组。此结果表明,卷曲乳杆菌CCFM1118可显著降低幽门螺杆菌感染患者幽门螺杆菌感染程度。
表2幽门螺杆菌阳性感染者招募人群分布情况
组别 | 人数(N) | 年龄 | 男/女 | 饮酒/不饮酒 | 吸烟/不吸烟 |
Placebo | 13 | 48.15±3.70 | 2/11 | 1/12 | 0/13 |
CCFM1118 | 17 | 54.22±2.70 | 9/10 | 3/16 | 2/17 |
表3不同组别幽门螺杆菌阳性患者的感染程度
组别 | 人数(N) | 阳性n | 阴性n | 阴性率(%) |
Placebo | 13 | 11 | 2 | 15.38 |
CCFM1118 | 17 | 5 | 12 | 70.59* |
注:*表示与安慰剂组相比差异显著(p<0.05)。
实施例6:卷曲乳杆菌的应用
卷曲乳杆菌CCFM1118可用于制备菌粉,菌粉的具体制备过程如下:
卷曲乳杆菌CCFM1118划线于MRS固体培养基上,37℃条件下培养48h,得到单菌落;挑取单菌落接种于MRS液体培养基中,37℃条件下培养18h进行活化,连续活化两代,得到活化液;将活化液按2%(v/v)的接种量接种于培养基中,37℃条件下培养18h,得到菌液;将菌液经8000g离心10min,得到菌泥;将菌泥用生理盐水清洗3次后用保护剂重悬至浓度为1×1010CFU/mL,得到菌悬液;将菌悬液在温度37℃下预培养60min后冻干,得到卷曲乳杆菌CCFM1118菌粉;
其中,培养基的制备方法为:使用以培养基总重量计87.7%的水将10%酶水解脱脂乳、0.5%葡萄糖、1.5%胰蛋白胨与0.3%酵母浸膏溶解,然后调整其pH为6.8,得到培养基;
保护剂的成分包含:130g/L脱脂奶粉。
准确称取2g卷曲乳杆菌CCFM1118菌粉溶解于10mL无菌生理盐水中,得到原始菌悬液;取0.5mL原始菌悬液加入4.5mL无菌生理盐水中,混匀,此时原始菌悬液稀释10倍,记为“n=10”,从稀释后的菌悬液中取0.5mL加入4.5mL无菌生理盐水中,此时原始菌悬液稀释100倍,记为“n=102”,以此类推将原始菌悬液稀释至1.0×108倍;取0.1mL稀释倍数为1.0×106(n=106)、1.0×107(n=107)和1.0×108(n=108)的菌悬液,分别用MRS固体培养基倒平板,厌氧箱中37℃培养2d~3d,进行活菌计数,每周测定一次,持续一个月,测定卷曲乳杆菌CCFM1118菌粉的储存稳定性,测定结果见图3。
由图3可知,卷曲乳杆菌CCFM1118菌粉的初始活菌数高于1010CFU/袋,符合产品规格;储存一个月的过程中,卷曲乳杆菌CCFM1118菌粉的活菌数与初始相比没有明显的下降,活菌数一直高于1010CFU/袋,表明卷曲乳杆菌CCFM1118菌粉在一个月的短期储存过程中性能比较稳定。
实施例7:卷曲乳杆菌的应用
卷曲乳杆菌CCFM1118可用于制备胶囊制品,胶囊制品的具体制备过程如下
卷曲乳杆菌CCFM1118划线于MRS固体培养基上,37℃条件下培养48h,得到单菌落;挑取单菌落接种于MRS液体培养基中,37℃条件下培养18h进行活化,连续活化两代,得到活化液;将活化液按2%(v/v)的接种量接种于培养基中,37℃条件下培养18h,得到菌液;将菌液经8000g离心10min,得到菌泥;将菌泥用生理盐水清洗3次后用保护剂重悬至浓度为1×1010CFU/mL,得到菌悬液;菌悬液添加至浓度为30g/L的海藻酸钠溶液中至浓度为2×109CFU/mL后,充分搅拌,使得卷曲乳杆菌CCFM1118的细胞均匀地分散于海藻酸钠溶液中,得到混合液;将混合液挤压到浓度为20g/L的氯化钙溶液中形成胶粒;待形成的胶粒静止固化30min后,过滤收集胶粒;将收集得到的胶粒进行冷冻干燥48h,得到粉剂;将粉剂装入到药用胶囊中,得到胶囊制品;
其中,培养基的制备方法为:使用以培养基总重量计87.7%的水将10%酶水解脱脂乳、0.5%葡萄糖、1.5%胰蛋白胨与0.3%酵母浸膏溶解,然后调整其pH为6.8,得到培养基。
实施例8:卷曲乳杆菌的应用
卷曲乳杆菌CCFM1118可用于制备片剂,片剂的具体制备过程如下:
卷曲乳杆菌CCFM1118划线于MRS固体培养基上,37℃条件下培养48h,得到单菌落;挑取单菌落接种于MRS液体培养基中,37℃条件下培养18h进行活化,连续活化两代,得到活化液;将活化液按2%(v/v)的接种量接种于培养基中,37℃条件下培养18h,得到菌液;将菌液经8000g离心10min,得到菌泥;将菌泥用生理盐水清洗3次后用保护剂重悬至浓度为1×1010CFU/mL,得到菌悬液;将菌悬液在温度37℃下预培养60min后冻干,得到卷曲乳杆菌CCFM1118菌粉;
其中,培养基的制备方法为:使用以培养基总重量计87.7%的水将10%酶水解脱脂乳、0.5%葡萄糖、1.5%胰蛋白胨与0.3%酵母浸膏溶解,然后调整其pH为6.8,得到培养基;
保护剂的成分包含:130g/L脱脂奶粉。
称取卷曲乳杆菌CCFM1118菌粉25.7重量份、淀粉55.0重量份、纤维素衍生物4.5重量份、羧甲基淀粉钠12.0重量份、滑石粉0.8重量份、蔗糖1.0重量份与水1.0重量份,得到原材料;将原材料混合,得到湿颗粒;将湿颗粒用中南制药机械厂的压片机进行压片后使用青州市益康中药机械有限公司的小型药物干燥机进行干燥,得到片剂。
实施例8:卷曲乳杆菌的应用
卷曲乳杆菌CCFM1118可用于制备发酵乳,发酵乳的具体制备过程如下:
卷曲乳杆菌CCFM1118划线于MRS固体培养基上,37℃条件下培养48h,得到单菌落;挑取单菌落接种于MRS液体培养基中,37℃条件下培养18h进行活化,连续活化两代,得到活化液;将活化液按2%(v/v)的接种量接种于培养基中,37℃条件下培养18h,得到菌液;将菌液经8000g离心10min,得到菌泥;将菌泥用生理盐水清洗3次后用保护剂重悬至浓度为1×1010CFU/mL,得到菌悬液;将菌悬液在温度37℃下预培养60min后冻干,得到卷曲乳杆菌CCFM1118菌粉;
其中,培养基的制备方法为:使用以培养基总重量计87.7%的水将10%酶水解脱脂乳、0.5%葡萄糖、1.5%胰蛋白胨与0.3%酵母浸膏溶解,然后调整其pH为6.8,得到培养基;
保护剂的成分包含:130g/L脱脂奶粉。
将卷曲乳杆菌CCFM1118菌粉与商业干粉发酵剂保加利亚乳杆菌和商业干粉发酵剂嗜热链球菌按照质量比1:1:1的比例混合,得到发酵剂;将糖添加至鲜奶中至浓度为50g/L,得到混合液;将混合液在65℃、20MPa的条件下进行均质后在95℃下保温杀菌5min,得到发酵原料;将发酵原料降温至35℃后以0.03%(v/v)的接种量将发酵剂接种至发酵原料中,于35℃下保温发酵16h,得到发酵乳;将发酵乳于42℃下放置4h进行凝乳后,在4℃下冷藏24h进行后熟,得到发酵乳成品。
实施例9:卷曲乳杆菌的应用
卷曲乳杆菌CCFM1118可用于制备豆奶,豆奶的具体制备过程如下:
卷曲乳杆菌CCFM1118划线于MRS固体培养基上,37℃条件下培养48h,得到单菌落;挑取单菌落接种于MRS液体培养基中,37℃条件下培养18h进行活化,连续活化两代,得到活化液;将活化液按2%(v/v)的接种量接种于培养基中,37℃条件下培养18h,得到菌液;将菌液经8000g离心10min,得到菌泥;将菌泥用生理盐水清洗3次后用保护剂重悬至浓度为1×1010CFU/mL,得到菌悬液;将菌悬液在温度37℃下预培养60min后冻干,得到卷曲乳杆菌CCFM1118菌粉;
其中,培养基的制备方法为:使用以培养基总重量计87.7%的水将10%酶水解脱脂乳、0.5%葡萄糖、1.5%胰蛋白胨与0.3%酵母浸膏溶解,然后调整其pH为6.8,得到培养基;
保护剂的成分包含:130g/L脱脂奶粉。
将大豆在温度80℃下浸泡2h后去除大豆皮,得到去皮大豆;将去皮大豆沥去浸泡水后加沸水磨浆,得到豆浆;将豆浆在高于80℃的温度条件下保温12min,得到熟豆浆;将熟豆浆用150目筛网过滤后离心分离,得到粗豆奶;将粗豆奶加热到温度140~150℃后迅速导入真空冷却室进行抽真空,使得粗豆奶中的异味物质随着水蒸汽迅速排出,得到熟豆奶;将熟豆奶降温至约37℃后在熟豆奶中添加卷曲乳杆菌CCFM1118菌粉至浓度为不低于1×106CFU/mL,得到豆奶(豆奶需在4℃下冷藏保存)。
实施例10:卷曲乳杆菌的应用
卷曲乳杆菌CCFM1118可用于制备果蔬饮料,果蔬饮料的具体制备过程如下:
卷曲乳杆菌CCFM1118划线于MRS固体培养基上,37℃条件下培养48h,得到单菌落;挑取单菌落接种于MRS液体培养基中,37℃条件下培养18h进行活化,连续活化两代,得到活化液;将活化液按2%(v/v)的接种量接种于培养基中,37℃条件下培养18h,得到菌液;将菌液经8000g离心10min,得到菌泥;将菌泥用生理盐水清洗3次后用保护剂重悬至浓度为1×1010CFU/mL,得到菌悬液;将菌悬液在温度37℃下预培养60min后冻干,得到卷曲乳杆菌CCFM1118菌粉;
其中,培养基的制备方法为:使用以培养基总重量计87.7%的水将10%酶水解脱脂乳、0.5%葡萄糖、1.5%胰蛋白胨与0.3%酵母浸膏溶解,然后调整其pH为6.8,得到培养基;
保护剂的成分包含:130g/L脱脂奶粉。
将新鲜水果和蔬菜洗净后榨汁,得到果蔬汁;将果蔬汁在温度140℃下高温热杀菌2秒,得到杀菌后的果蔬汁;将杀菌后的果蔬汁降温至约37℃后在杀菌后的果蔬汁中添加卷曲乳杆菌CCFM1118菌粉至浓度为不低于1×106CFU/mL,得到果蔬饮料(果蔬饮料需在4℃下冷藏保存)。
实施例10:卷曲乳杆菌的应用
卷曲乳杆菌CCFM1118可用于制备乳饮品,乳饮品的具体制备过程如下:
卷曲乳杆菌CCFM1118划线于MRS固体培养基上,37℃条件下培养48h,得到单菌落;挑取单菌落接种于MRS液体培养基中,37℃条件下培养18h进行活化,连续活化两代,得到活化液;将活化液按2%(v/v)的接种量接种于培养基中,37℃条件下培养18h,得到菌液;将菌液经8000g离心10min,得到菌泥;将菌泥用生理盐水清洗3次后用保护剂重悬至浓度为1×1010CFU/mL,得到菌悬液;将菌悬液在温度37℃下预培养60min后冻干,得到卷曲乳杆菌CCFM1118菌粉;
其中,培养基的制备方法为:使用以培养基总重量计87.7%的水将10%酶水解脱脂乳、0.5%葡萄糖、1.5%胰蛋白胨与0.3%酵母浸膏溶解,然后调整其pH为6.8,得到培养基;
保护剂的成分包含:130g/L脱脂奶粉。
将脱脂奶在95℃热杀菌20min后冷却至4℃,得到原料;在原料中添加卷曲乳杆菌CCFM1118菌粉至浓度为不低于1×106CFU/mL,得到乳饮品(乳饮品需在4℃下冷藏保存)。
虽然本发明已以较佳实施例公开如上,但其并非用以限定本发明,任何熟悉此技术的人,在不脱离本发明的精神和范围内,都可做各种的改动与修饰,因此本发明的保护范围应该以权利要求书所界定的为准。
序列表
<110> 江南大学
<120> 一株能够预防和/或治疗幽门螺杆菌感染的卷曲乳杆菌
<160> 1
<170> PatentIn version 3.3
<210> 1
<211> 1165
<212> DNA
<213> 卷曲乳杆菌
<220>
<221> misc_feature
<222> (4)..(9)
<223> n is a, c, g, or t
<220>
<221> misc_feature
<222> (11)..(11)
<223> n is a, c, g, or t
<220>
<221> misc_feature
<222> (13)..(14)
<223> n is a, c, g, or t
<220>
<221> misc_feature
<222> (1082)..(1082)
<223> n is a, c, g, or t
<220>
<221> misc_feature
<222> (1087)..(1087)
<223> n is a, c, g, or t
<220>
<221> misc_feature
<222> (1151)..(1151)
<223> n is a, c, g, or t
<220>
<221> misc_feature
<222> (1154)..(1158)
<223> n is a, c, g, or t
<220>
<221> misc_feature
<222> (1164)..(1165)
<223> n is a, c, g, or t
<400> 1
gagnnnnnnt ncnngcctta gacggctcct tcccgaaggt taggccaccg gctttgggca 60
ttgcagactc ccatggtgtg acgggcggtg tgtacaaggc ccgggaacgt attcaccgcg 120
gcgtgctgat ccgcgattac tagcgattcc agcttcgtgc agtcgagttg cagactgcag 180
tccgaactga gaacagcttt cagagattcg cttgccttcg caggctcgct tctcgttgta 240
ctgcccattg tagcacgtgt gtagcccagg tcataagggg catgatgact tgacgtcatc 300
cccaccttcc tccggtttgt caccggcagt ctcattagag tgcccaactt aatgctggca 360
actaataaca agggttgcgc tcgttgcggg acttaaccca acatctcacg acacgagctg 420
acgacagcca tgcaccacct gtcttagcgt ccccgaaggg aactttgtat ctctacaaat 480
ggcactagat gtcaagacct ggtaaggttc ttcgcgttgc ttcgaattaa accacatgct 540
ccaccgcttg tgcgggcccc cgtcaattcc tttgagtttc aaccttgcgg tcgtactccc 600
caggcggagt gcttaatgcg ttagctacag cactgagagg cggaaacctc ccaacactta 660
gcactcatcg tttacggcat ggactaccag ggtatctaat cctgttcgct acccatgctt 720
tcgagcctca gcgtcagttg cagaccagag agccgccttc gccactggtg ttcttccata 780
tatctacgca ttccaccgct acacatggag ttccactctc ctcttctgca ctcaagaaaa 840
acagtttccg atgcagttcc tcggttaagc cgagggcttt cacatcagac ttattcttcc 900
gcctgcgctc gctttacgcc caataaatcc ggacaacgct tgccacctac gtattaccgc 960
ggctgctggc acgtagttag ccgtgacttt ctggttgatt accgtcaaat aaaggccagt 1020
tactacctct atccttcttc accaacaaca gagctttacg atccgaaaac ctctcactca 1080
cncggcntgc tccatcagac ttgcgtcatt gtggaagatt ccctactgct gcctccgtag 1140
aagttggggc ngtnnnnnct cagnn 1165
Claims (9)
1.一株卷曲乳杆菌(Lactobacillus crispatus),其特征在于,所述卷曲乳杆菌保藏于广东省微生物菌种保藏中心,保藏编号为GDMCC No.61012,保藏日期为2020年05月06日。
2.一种幽门螺杆菌抑制剂,其特征在于,所述幽门螺杆菌抑制剂含有权利要求1所述卷曲乳杆菌,所述幽门螺杆菌为幽门螺杆菌(Helicobacter pylori)SS1。
3.权利要求1所述卷曲乳杆菌在制备预防和/或治疗幽门螺杆菌SS1感染的产品中的应用。
4.一种产品,其特征在于,所述产品含有权利要求1所述卷曲乳杆菌。
5.如权利要求4所述的产品,其特征在于,所述产品中,权利要求1所述卷曲乳杆菌的活菌数为不低于5×109 CFU/mL或5×109 CFU/g。
6.如权利要求4或5所述的产品,其特征在于,所述产品包含食品或药品。
7.如权利要求6所述的产品,其特征在于,所述药品含有权利要求1所述卷曲乳杆菌、药物载体和/或药用辅料。
8.如权利要求7所述的产品,其特征在于,所述药品的剂型为粉剂、颗粒剂、胶囊剂、片剂、丸剂或口服液。
9.如权利要求6所述的产品,其特征在于,所述食品为保健食品;或所述食品为使用含有权利要求1所述卷曲乳杆菌的发酵剂生产得到的乳制品、豆制品或果蔬制品;或所述食品为含有权利要求1所述卷曲乳杆菌的饮料或零食。
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010479611.4A CN111548970B (zh) | 2020-05-29 | 2020-05-29 | 一株能够预防和/或治疗幽门螺杆菌感染的卷曲乳杆菌 |
PCT/CN2021/095766 WO2021238907A1 (zh) | 2020-05-29 | 2021-05-25 | 一株能够预防和/或治疗幽门螺杆菌感染的卷曲乳杆菌 |
EP21814138.0A EP4144833A4 (en) | 2020-05-29 | 2021-05-25 | LACTOBACILLUS CRISPATUS STRAIN FOR PREVENTING AND/OR TREATING HELICOBACTER PYLORI INFECTION |
US17/709,527 US20220218769A1 (en) | 2020-05-29 | 2022-03-31 | Strain of Lactobacillus crispatus Capable of Preventing and/or Treating Helicobacter pylori Infection |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010479611.4A CN111548970B (zh) | 2020-05-29 | 2020-05-29 | 一株能够预防和/或治疗幽门螺杆菌感染的卷曲乳杆菌 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN111548970A CN111548970A (zh) | 2020-08-18 |
CN111548970B true CN111548970B (zh) | 2021-03-26 |
Family
ID=71999203
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010479611.4A Active CN111548970B (zh) | 2020-05-29 | 2020-05-29 | 一株能够预防和/或治疗幽门螺杆菌感染的卷曲乳杆菌 |
Country Status (4)
Country | Link |
---|---|
US (1) | US20220218769A1 (zh) |
EP (1) | EP4144833A4 (zh) |
CN (1) | CN111548970B (zh) |
WO (1) | WO2021238907A1 (zh) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111548970B (zh) * | 2020-05-29 | 2021-03-26 | 江南大学 | 一株能够预防和/或治疗幽门螺杆菌感染的卷曲乳杆菌 |
CN114214230B (zh) * | 2021-12-09 | 2023-08-08 | 江南大学 | 一株具有共聚幽门螺杆菌能力的北酸乳杆菌及其应用 |
CN114231449B (zh) * | 2021-12-09 | 2023-08-25 | 江南大学 | 一株具有共聚幽门螺杆菌能力的嗜酸乳杆菌及其应用 |
CN116024129A (zh) * | 2022-11-29 | 2023-04-28 | 光明乳业股份有限公司 | 一株能够与幽门螺杆菌共聚集的卷曲乳杆菌及其应用 |
CN116103197B (zh) * | 2022-12-19 | 2024-01-02 | 威凯海思(山东)生物工程有限公司 | 一种对幽门螺旋杆菌有抑制作用的嗜热链球菌及其应用 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1357038A (zh) * | 1999-06-21 | 2002-07-03 | Vsl制药有限公司 | 乳酸细菌的组合及其用于预防和/或治疗感染和炎症的用途 |
CN103648511A (zh) * | 2011-06-08 | 2014-03-19 | 有机平衡有限公司 | 喷雾干燥的乳杆菌属菌株/细胞及其对抗幽门螺杆菌的用途 |
CN103987393A (zh) * | 2011-09-09 | 2014-08-13 | G·莫格纳 | 能够恢复在胃酸过多的药物治疗期间丧失的胃本身的屏障效应的包括与益生菌联合的n-乙酰半胱氨酸和/或微胶囊化的胃保护性溶菌酶的组合物 |
CN105163747A (zh) * | 2011-04-20 | 2015-12-16 | G·莫格纳 | 能够恢复在胃酸过多的药物治疗期间丧失的胃的屏障效应的包含益生菌的组合物 |
WO2019211382A1 (en) * | 2018-05-03 | 2019-11-07 | Crigasseni Ag | Probiotic bacterial strains producing antimicrobial proteins and compositions comprising these for use in the treatment of diarrheal and other microbial diseases |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20190002036A (ko) * | 2017-06-29 | 2019-01-08 | 수원대학교산학협력단 | 블루베리 추출물을 포함하는 장내 유익균의 증식을 위한 프리바이오틱스 및 이의 용도 |
CN111548970B (zh) * | 2020-05-29 | 2021-03-26 | 江南大学 | 一株能够预防和/或治疗幽门螺杆菌感染的卷曲乳杆菌 |
CN114317334B (zh) * | 2021-12-17 | 2023-06-13 | 江南大学 | 一株能够与幽门螺杆菌共聚集的清酒乳杆菌及其应用 |
CN116024129A (zh) * | 2022-11-29 | 2023-04-28 | 光明乳业股份有限公司 | 一株能够与幽门螺杆菌共聚集的卷曲乳杆菌及其应用 |
-
2020
- 2020-05-29 CN CN202010479611.4A patent/CN111548970B/zh active Active
-
2021
- 2021-05-25 EP EP21814138.0A patent/EP4144833A4/en active Pending
- 2021-05-25 WO PCT/CN2021/095766 patent/WO2021238907A1/zh unknown
-
2022
- 2022-03-31 US US17/709,527 patent/US20220218769A1/en active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1357038A (zh) * | 1999-06-21 | 2002-07-03 | Vsl制药有限公司 | 乳酸细菌的组合及其用于预防和/或治疗感染和炎症的用途 |
CN105163747A (zh) * | 2011-04-20 | 2015-12-16 | G·莫格纳 | 能够恢复在胃酸过多的药物治疗期间丧失的胃的屏障效应的包含益生菌的组合物 |
CN103648511A (zh) * | 2011-06-08 | 2014-03-19 | 有机平衡有限公司 | 喷雾干燥的乳杆菌属菌株/细胞及其对抗幽门螺杆菌的用途 |
CN103987393A (zh) * | 2011-09-09 | 2014-08-13 | G·莫格纳 | 能够恢复在胃酸过多的药物治疗期间丧失的胃本身的屏障效应的包括与益生菌联合的n-乙酰半胱氨酸和/或微胶囊化的胃保护性溶菌酶的组合物 |
WO2019211382A1 (en) * | 2018-05-03 | 2019-11-07 | Crigasseni Ag | Probiotic bacterial strains producing antimicrobial proteins and compositions comprising these for use in the treatment of diarrheal and other microbial diseases |
Non-Patent Citations (1)
Title |
---|
Ning Wang.Resistant gastric environment of Lactobacillus crispatus from stomach inhibits Helicobacter pylori colonization and attenuates gastric inflammation.《Research Square》.2019,第1-24页. * |
Also Published As
Publication number | Publication date |
---|---|
EP4144833A1 (en) | 2023-03-08 |
CN111548970A (zh) | 2020-08-18 |
US20220218769A1 (en) | 2022-07-14 |
EP4144833A4 (en) | 2024-03-06 |
WO2021238907A1 (zh) | 2021-12-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN111607538B (zh) | 一株鼠李糖乳杆菌及其在抑制幽门螺杆菌中的应用 | |
CN111548970B (zh) | 一株能够预防和/或治疗幽门螺杆菌感染的卷曲乳杆菌 | |
CN112143680B (zh) | 具有抗氧化功效副干酪乳杆菌zjuids05及其应用 | |
CN114540243A (zh) | 一种能够预防和或治疗幽门螺杆菌感染的鼠李糖乳杆菌及其应用 | |
CN113337431B (zh) | 一株抑制幽门螺杆菌的罗伊氏乳杆菌nsl0501及其生物菌剂和应用 | |
CN114085792B (zh) | 一种用于防治结肠癌的副干酪乳杆菌及其应用 | |
CN111471626A (zh) | 一株能够抑制幽门螺杆菌的瑞士乳杆菌及其应用 | |
TWI739495B (zh) | 可促進排便的組合物及其用途 | |
CN116024130B (zh) | 一株降血尿酸发酵乳杆菌a21215及其应用 | |
CN116445321B (zh) | 降核苷降血尿酸罗伊氏乳杆菌a21160及其应用 | |
CN114774326B (zh) | 一株抑制幽门螺旋杆菌的植物乳杆菌a21136及其应用 | |
CN114958658B (zh) | 一株抑制幽门螺旋杆菌的鼠李糖乳杆菌a21149及其应用 | |
CN114214230B (zh) | 一株具有共聚幽门螺杆菌能力的北酸乳杆菌及其应用 | |
CN114317334B (zh) | 一株能够与幽门螺杆菌共聚集的清酒乳杆菌及其应用 | |
CN114774315A (zh) | 鼠李糖乳杆菌菌株LRa05在制备增强免疫力制品和/或缓解湿疹制品方面的用途 | |
CN111690571B (zh) | 一株可清除丙烯酰胺的植物乳杆菌及其应用 | |
CN116024129A (zh) | 一株能够与幽门螺杆菌共聚集的卷曲乳杆菌及其应用 | |
CN111560325A (zh) | 一株能够调节肠道紧密连接蛋白的发酵乳杆菌及其应用 | |
CN109846044B (zh) | 具有改善记忆、提高免疫力的益生菌组合物及其制备方法 | |
CN115119940A (zh) | 嗜酸乳杆菌LA85和乳双歧杆菌BLa80在抑制幽门螺旋杆菌上的应用 | |
CN113122471A (zh) | 一株高利用低聚半乳糖的假小链双歧杆菌及其应用 | |
CN114231449B (zh) | 一株具有共聚幽门螺杆菌能力的嗜酸乳杆菌及其应用 | |
CN112029676B (zh) | 一种有利于提高免疫力的益生菌组合及其应用 | |
CN114774314B (zh) | 一株鼠李糖乳杆菌菌株LRa05及其用途与产品 | |
CN109700033B (zh) | 一种调节肠道、预防便秘的益生菌组合物及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |